Jeffrey Zhao

Jeffrey Zhao

Auto-generated profile, based on publicly available information

Jeffrey Zhao

Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
YPYoonseok Park
Yoonseok Park
KKKyeongha Kwon
Kyeongha Kwon
SKSung Soo Kwak
Sung Soo Kwak
DYDa Som Yang
Da Som Yang
JKJean Won Kwak
Jean Won Kwak
John A. RogersJohn A. Rogers
John A. Rogers
Soft, wireless sensors monitor the temperature and interface pressure of the patient’s skin for compression therapy.

31 March 2021 in Advanced Functional Materials
Verified
Journal Article
Closed access
PDF file
HZHao Zhang
Hao Zhang
HZHangbo Zhao
Hangbo Zhao
XZXingyue Zhao
Xingyue Zhao
CXChenkai Xu
Chenkai Xu
DFDaniel Franklin
Daniel Franklin
John A. RogersJohn A. Rogers
John A. Rogers

1 May 2020 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
MAMegan Arthur
Megan Arthur
NFNicole M. Fett
Nicole M. Fett
ELEmile Latour
Emile Latour
HJHeidi Jacobe
Heidi Jacobe
EKElaine Kunzler
Elaine Kunzler
KLKelly Lo
Kelly Lo
Morphea (localized scleroderma) is a rare sclerosing disorder of the skin and subcutaneous tissue that affects patients of all ages.1-3 Patients with extensive involvement unresponsive to phototherapy, with facial involvement, or with involvement traversing joints require systemic treatment to prevent disease progression and its associated morbidity. Experts recommend treatment with methotrexate (MTX) for these patients.2-6 This recommendation is based on a randomized, double-blind, placebo-controlled clinical trial in a pediatric population comparing the combination of prednisone for 3 months and MTX for 12 months vs prednisone alone for 3 months.7 Those who received MTX demonstrated improved skin scores and were less likely to experience disease relapse compared with those who received placebo. In addition, several small retrospective studies and a prospective study have further supported the value and safety of MTX, with or without systemic corticosteroids (SCSs), for the treatment of morphea.8-15 For some patients, treatment with MTX is ineffective, not well tolerated, or contraindicated. Studies suggest that approximately 25% to 30% of patients with morphea will not show clinical improvement with MTX.7,12 In this subset of patients, a trial of mycophenolate mofetil (MMF) or mycophenolic acid (MPA)—referred to herein as mycophenolate—is recommended, although evidence supporting this practice is based on small case series.2,4,5

3 October 2019 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
KTKyle Tegtmeyer
Kyle Tegtmeyer
JZJeffrey Zhao
Jeffrey Zhao
NMNolan J. Maloney
Nolan J. Maloney
GAGiancarlo Atassi
Giancarlo Atassi
MBMolly Beestrum
Molly Beestrum
PLPeter Lio
Peter Lio
Purpose: Tofacitinib citrate is an oral Janus kinase 1/3 inhibitor approved for rheumatoid arthritis, ulcerative colitis, and active psoriatic arthritis. Tofacitinib is being increasingly used off-label for dermatological conditions, with varying efficacy across recent studies. A review of these studies will be a helpful resource for dermatologists considering the use of tofacitinib for conditions refractory to first-line therapies. Materials and methods: MEDLINE, Embase, CINAHL Plus, Cochrane Library, Scopus, Web of Science, Clinicaltrials.gov, and the WHO International Clinical Trials Registry Platform were all searched for articles and trials mentioning the term ‘tofacitinib’, then manually reviewed to identify published data on off-label uses of tofacitinib. The article was structured according to the quality of the evidence available. Results: Tofacitinib appears to show strong efficacy for numerous dermatologic conditions. Randomized controlled trial data is available for atopic dermatitis, alopecia areata, and plaque psoriasis. Case report and case series data is available for numerous other dermatologic conditions. Conclusion: While tofacitinib has a wide array of immunoregulatory properties, making it a possible candidate for treating many dermatologic conditions refractory to other treatments, further testing is needed to better characterize its efficacy and utility moving forward, as well as its safety and adverse effect profile.

2 April 2019 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
NMNolan J. Maloney
Nolan J. Maloney
JZJeffrey Zhao
Jeffrey Zhao
KTKyle Tegtmeyer
Kyle Tegtmeyer
ELErnest Y. Lee
Ernest Y. Lee
KCKyle Cheng
Kyle Cheng
Purpose: Apremilast is a phosphodiesterase-4 inhibitor FDA approved for psoriatic arthritis and moderate to severe plaque psoriasis. In recent years, multiple studies have suggested other potential uses for apremilast in dermatology. A summary of these various studies will be a valuable aid to dermatologists considering apremilast for an alternative indication. Materials and methods: The PubMed/MEDLINE and ClinicalTrials.gov databases were queried with the term ‘apremilast,’ with results manually screened to identify published data on off-label uses of apremilast. The article was structured by the quality of evidence available. Results: Apremilast use in dermatology beyond plaque psoriasis and psoriatic arthritis is frequently described in the literature, with a mixture of positive and negative results. Randomized controlled data is available for Behçet’s disease, hidradenitis suppurativa, nail/scalp/palmoplantar psoriasis, alopecia areata, and atopic dermatitis. Conclusion: The relatively safe adverse effect profile of apremilast and its broad immunomodulatory characteristics may make it a promising option in the future for patients with difficult to treat diseases in dermatology, refractory to first line therapies, but further studies will be necessary to clarify its role.

22 April 2020 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
KTKyle Tegtmeyer
Kyle Tegtmeyer
GAGiancarlo Atassi
Giancarlo Atassi
JZJeffrey Zhao
Jeffrey Zhao
NMNolan J. Maloney
Nolan J. Maloney
PLPeter Lio
Peter Lio
Purpose: Anakinra (Kineret®) is an interleukin-1 receptor antagonist (IL-1Ra) FDA approved for use in rheumatoid arthritis and in neonatal-onset multisystem inflammatory disease (NOMID). It has been used off-label for a variety of dermatologic conditions. A review of the available studies and cases of these off-label uses would be valuable to the dermatologist considering alternative treatments for these oftentimes poorly studied conditions. Materials and methods: The PubMed/MEDLINE, EMBASE, Scopus, and ClinicalTrials.gov databases were searched with the term ‘anakinra.’ Results were manually screened to identify published data on off-label uses of anakinra in dermatologic conditions and systemic conditions with prominent dermatologic manifestations. Results: Anakinra appears to show efficacy for numerous dermatologic conditions, with the strongest evidence for hidradenitis suppurativa, Bechet’s disease, Muckle-Wells syndrome, and SAPHO syndrome. Case reports and case series data are available for numerous other dermatologic conditions. Conclusion: Anakinra is a potential option for patients with certain difficult-to-treat dermatologic diseases, given its relatively benign adverse effect profile and its effectiveness in a wide array of conditions. Overall, anakinra appears to be a promising option in the treatment of numerous dermatologic inflammatory conditions refractory to first line therapies, but further and higher-quality data is needed to clarify its therapeutic role.